Earnings Overview#
ACADIA Pharmaceuticals Inc. (ACAD) has released its financial results for the first quarter of 2026, showing a significant earnings miss. The company reported earnings per share (EPS) of $0.02, which is 60% lower than the expected EPS of $0.05. Additionally, revenue came in at $268 million, falling short of the projected $280.92 million.
Company Performance#
Despite the earnings miss, ACADIA showed year-over-year revenue growth of 11%. This increase is largely attributed to strong sales from its commercial products, particularly DAYBUE, which saw a 20% rise in net sales, reaching $101 million. Another product, NUPLAZID, also contributed with a 6% increase in sales. The company maintains a solid gross profit margin of 61% and has a strong cash position of $851 million, up from $820 million in the previous quarter.
Financial Highlights#
- Revenue: $268 million, up 11% year-over-year
- Earnings per share: $0.02, below the forecast of $0.05
- DAYBUE net sales: $101 million, up 20% year-over-year
- NUPLAZID net sales: $167 million, up 6% year-over-year
- Cash balance: $851 million, indicating strong financial health with more cash than debt.
Market Reaction#
Following the earnings report, ACADIA's stock price increased by 1.25% in aftermarket trading, reaching $22.63. This rise contrasts with a 3.89% decline during regular trading hours, reflecting mixed investor sentiment. Over the past year, the stock has delivered a notable 48% return, and it currently trades at a price-to-earnings (P/E) ratio of 9.65, suggesting it may be undervalued compared to its growth potential.